Mechanisms of the analgesic effect of calcitonin on chronic pain by alteration of receptor or channel expression

Abstract

The polypeptide hormone calcitonin is well known clinically for its ability to relieve osteoporotic back pain and neuropathic pain such as spinal canal stenosis, diabetic neuropathy, chemotherapy-induced neuropathy, and complex regional pain syndrome. Because the analgesic effects of calcitonin have a broad range, the underlying mechanisms of pain relief by calcitonin are largely unknown. However, recent studies using several types of chronic pain models combined with various methods have been gradually clarifying the mechanism. Here, we review the mechanisms of the analgesic action of calcitonin on ovariectomy-induced osteoporotic and neuropathic pain. The analgesic action of calcitonin may be mediated by restoration of serotonin receptors that control selective glutamate release from C-afferent fibers in ovariectomized rats and by normalization of sodium channel expression in damaged peripheral nerves. Serotonin receptors are reduced or eliminated by the relatively rapid reduction in estrogen during the postmenopausal period, and damaged nerves exhibit hyperexcitability due to abnormal expression of Na⁺ channel subtypes. In addition, in chemotherapy-induced peripheral neuropathy, inhibition of signals related to transient receptor potential ankyrin-1 and melastatin-8 is proposed to participate in the anti-allodynic action of calcitonin. Further, an unknown calcitonin-dependent signal appears to be present in peripheral nervous tissues and may be activated by nerve injury, resulting in regulation of the excitability of primary afferents by control of sodium channel transcription in dorsal root ganglion neurons. The calcitonin signal in normal conditions may be non-functional because no target is present, and ovariectomy or nerve injury may induce a target. Moreover, it has been reported that calcitonin reduces serotonin transporter but increases serotonin receptor expression in the thalamus in ovariectomized rats. These data suggest that calcitonin could alleviate lower back pain in patients with osteoporosis or neuropathic pain by the alteration in receptor or channel expression.

Keywords

Peripheral nerve excitability neuropathic pain osteoporosis ovariectomy estrogen serotonin chronic constriction injury model analgesia

Introduction

Calcitonin (CT), a 32-amino acid polypeptide released from the parafollicular C cells of the mammalian thyroid gland, is a major regulatory hormone of calcium homeostasis¹ and plays only during periods of calcium stress, such as growth, pregnancy, lactation, and menopause. The effect is exerted via the activation of the CT receptor, a G-protein-coupled receptor with a seven-transmembrane domain. CT receptors are broadly distributed not only in osteoclasts but also in brain, ovary, kidney, stomach, and skeletal muscles, implying that CT may exert a wide range of effects on biological functions. One of the main functions of CT is to provide relief from severe pain associated with fractures,^2,3 post-osteoporotic fractures,^3,4 and Paget’s disease.⁴ Thus, an early assumption was that the analgesic effect of CT is due to an increase in bone mass. However, the analgesic effect of CT is clearly distinct from the increase in bone mass as observed by the time course of these events. The analgesic effect becomes significant after three to four weeks, before an increase in bone mass. A different mechanism is, therefore, likely regarding the analgesic effect of CT on patients suffering from osteoporosis. In addition, CT ameliorates various types of neuropathic pain associated with lumbar spinal canal stenosis,⁵ diabetic neuropathy,⁶ reflex sympathetic dystrophy,⁷ and post-herpetic neuralgia.⁸ CT is recently shown to inhibit the development of complex regional pain syndrome after stroke.⁹ The primary cause of these chronic types of pain may be the hyperexcitability of the peripheral nervous system. The excitability of nerves is preferentially controlled by the density of sodium and potassium channels, and by expression of particular sodium channel subtypes. Nevertheless, the analgesic mechanisms of CT remain poorly understood. On the other hand, accumulating evidence supports the idea that CT exerts its actions through changes in gene expression.^10–14 For instance, CT inhibits bone resorption by activation of protein kinase A and protein kinase C.¹² Activated protein kinase A induces a reduction in CT receptor mRNA, which negatively controls the effect of CT.¹³ Furthermore, in the rat thalamus, CT reduces serotonin (5-HT) transporters and increases 5-HT_1A receptors.¹⁴ These data suggest that a CT-activated signaling pathway regulates nociceptive transmission by controlling expression of various genes.

Recent electrophysiological studies combined with various techniques, especially molecular biology, suggest possible mechanisms for the action of CT in the peripheral or central nervous system. In this paper, we review the underlying mechanisms and efficacies of CT as an analgesic substance, based on observations in various types of chronic pain models.

Mechanisms of the analgesic effect of CT on ovariectomized (OVX) rats

Background for the analysis of OVX rats

As shown in Figure 1, the back pain in osteoporotic patients may occur as a result of mechanical stress that leads to direct stimulation of nociceptors that innervate bone marrow¹⁵ and algesic substances released from injured cells following fractures. In addition, back pain in the absence of fractures may occur as a result of activation of nociceptors by acids and algesic substances released by osteoclastic bone resorption.

Figure 1.

Analgesic effect of CT against the pain that accompanies postmenopausal osteoporosis.

Menopause is a major cause of osteoporosis in humans.¹⁶ One important change following menopause is depletion of estrogen, which regulates expression of various genes.¹⁷ Thus, depletion of estrogen influences the expression of receptors and channels that are required for the modulation of nociceptive transmission.

Based on the results obtained from OVX rats,^18–21 OVX-induced hyperalgesia may be due to a dysfunction of the descending serotonergic inhibitory system that controls nociceptive transmission at the spinal dorsal horn level. This dysfunction likely enhances the back pain in osteoporotic patients (Figure 1).

When CT is administered to patients, a period of about a month is required before the back pain is relieved.²² Repeated administration of CT inhibits OVX-induced hyperalgesia in rats with a similar time course as that seen in patients.

The analgesic effect of CT on OVX rats

OVX rats with osteoporosis exhibit hyperalgesia as seen with the tail withdrawal test. The analgesic effect is alleviated by repetitive, subcutaneous injections of CT in a dose-dependent manner¹⁸; this effect becomes significant after three to four weeks of treatment, before an increase in bone mass. Because these results are similar to the clinical effect of CT in patients, this rat model seems appropriate for studying the analgesic mechanisms of CT.

c-Fos expression in spinal cord neurons has been used as a functional marker of nociception in many studies.^23–28 Takayama et al.²¹ demonstrate that the number of c-Fos-immunoreactive neurons in the spinal dorsal horn is significantly increased in response to acute noxious stimuli in OVX rats, particularly in the superficial laminae, compared to sham rats, indicating that OVX enhances nociception in rats. Repeated CT injections suppress the number of c-Fos-positive neurons in the superficial laminae as seen with the formalin test.²¹ These results behaviorally confirm the OVX-induced hyperalgesia and CT-induced anti-hyperalgesia.^18,20

Involvement of the serotonergic system in the CT-induced analgesic effect in OVX rats

The central serotonergic and noradrenergic systems originating from the brain stem contribute to modulation of nociceptive transmission.^29–33 In particular, the serotonergic system likely contributes to the analgesic effect of CT.^34,35 Thus, involvement of the serotonergic system is examined using p-chlorophenylalanine (PCPA) and methiothepin, an inhibitor of 5-HT biosynthesis and a broad 5-HT receptor antagonist, respectively. In OVX rats, the analgesic effect of CT is completely inhibited by intraperitoneal injection of PCPA.¹⁸ Moreover, suppression of c-Fos expression by CT in OVX rats is abolished by PCPA.²¹ Consistently, the amount of 5-HT is decreased, and the activity of the serotonergic system is decreased after PCPA injection.¹⁸ Furthermore, the CT-induced analgesic effect is completely eliminated 60 min after methiothepin injection.³⁶ These data support the idea that the serotonergic system may be involved in CT-mediated analgesia in postmenopausal patients.

Serotonergic dysfunction in the spinal dorsal horn of OVX rats and its recovery following CT treatment

The substantia gelatinosa (SG) (lamina II) of the spinal dorsal horn plays a critical role in the modulation of nociceptive transmission from the periphery to the central nervous system.^37–41 Fine myelinated Aδ- and unmyelinated C-afferents, many of which carry nociceptive information, terminate preferentially in the SG,^37,42–46 and the majority of SG neurons are excited by noxious stimulation.^47,48 Further, SG is the main target of the descending serotonergic system.⁴⁹

A blind patch-clamp study in OVX rat spinal cord slices demonstrated that presynaptic 5-HT-induced inhibition of glutamatergic transmission evoked by stimulating C-afferent fibers is reduced. This effect is restored after repeated injections of CT. Intriguingly, no such effect was observed after Aδ-afferent stimulation¹⁹ (Figure 2). A similar loss of presynaptic inhibition is observed for spontaneous transmitter release.¹⁹ This inhibition is mimicked by a 5-HT_1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin hydrobromide (8-OH-DPAT). Nevertheless, this effect is not antagonized by the 5-HT_1A receptor antagonist, WAY100635.¹⁹ This action of 8-OH-DPAT is consistent with the observation using autoradiography that the number of ³H-8-OH-DPAT binding sites is decreased by 20% to 30% after either neonatal capsaicin treatment or dorsal rhizotomy, which eliminates C-fibers.⁵⁰ Furthermore, the binding of ³H-8-OH-DPAT to the spinal cord is reduced in OVX rats. This reduction in ³H-8-OH-DPAT binding is restored when OVX rats are chronically treated with CT.^19,20 Consistent with these observations, behavioral examination demonstrates that OVX rats exhibit hyperalgesia, which is alleviated by CT administration.^18,20 Altogether, these results indicate that hyperalgesia and CT-induced anti-hyperalgesia may be attributed to a change in the number of 5-HT receptors expressed at C-afferent terminals. As observed by the resistance to WAY100635, the participating receptor appears to be a 5-HT_1A-like receptor but not 5-HT_1A.¹⁹ This idea was further confirmed by polymerase chain reaction studies, which showed no expression of 5-HT_1A receptor mRNA in rat dorsal root ganglion (DRG) neurons.^51,52 This change in the number of 5-HT receptors could underlie the analgesic effects of CT on osteoporotic pain in humans.

Figure 2.

Possible mechanisms of OVX-induced hyperalgesia and its relief by CT treatment in spinal SG neurons in rats. 5-HT_1A-like receptors present on C-fiber terminals, the activation of which decreases the release of glutamate, are reduced in OVX rats, leading to hyperalgesia. CT treatment of OVX rats restores the number of receptors to normal, which results in anti-hyperalgesia. On the other hand, the decrease in glutamate released from Aδ-fiber terminals via the activation of other 5-HT receptors (white bar) does not change.

CT may be an exceptional analgesic substance that acts by restoring the density of 5-HT_1A-like receptors in C-fiber terminals (Figure 2). Considering that C-fibers convey predominantly diffuse and long-lasting pain information, 5-HT_1A-like receptors may play an important role in chronic pain transmission.

Ineffectiveness of estrogen treatment on hyperlagesia long term after OVX

In clinical studies, estrogen treatment is common in postmenopausal women with recurrent back pain, but this hormone replacement has no appreciable effect on continuous pain.⁵³ Most reviews have determined that CT treatment is preferable to hormone replacement for the alleviation of pain that accompanies osteoporosis,^54–56 despite the fact that osteoporosis and the accompanying pain are accelerated by the reduction in estrogen levels. Distinct from the clinical view, animal studies have shown that estrogen treatment reduces OVX-induced hyperalgesia.^20,57 The discrepancy in clinical and animal study outcomes may be due to the timing of administration of estrogen after depletion of the hormone. Estrogen injected three weeks after OVX mimics the effects of CT and prevents the OVX-induced decrease in 5-HT_1A-like receptor expression. Nevertheless, injection of estrogen 15 weeks after OVX has no significant effect, although the effects of CT are observed regardless of the timing of CT injection.²⁰ These results suggest that the estrogen receptor (ER) is down-regulated gradually after OVX.

ERs are expressed in rat Schwann cells⁵⁸ and DRG neurons.⁵⁹ Autoregulation of ER by its ligand has been the subject of many previous studies.^60–66 In rats 11 days after OVX, ER mRNA in rat DRG neurons is upregulated.⁶¹ Following long-term OVX (three months post-operation), the levels of ER expression are significantly reduced in rat brain.⁶⁶ Another study showed that at 49 weeks after OVX, pituitary ER mRNA levels are decreased by 55%.⁶⁵ The long-term change in the degree of ER expression after OVX should be studied in the peripheral nervous system. The ineffectiveness of estradiol on OVX-induced hyperalgesia may be attributed to the down-regulation of ERs during the 15 weeks after the operation. A decrease in ERs may be one of the reasons that estrogen is not recommended for the treatment of back pain associated with osteoporosis.

Other mechanisms of the anti-hyperalgesic effects of CT in OVX rats

A recent review shows that the voltage-gated sodium channels, Nav1.3, Nav1.7, Nav1.8, and Nav1.9, play pivotal roles in nociceptive transmission.⁶⁷ Nav1.3, a low-threshold, tetrodotoxin (TTX)-sensitive sodium channel, is expressed in embryonic but not adult DRG neurons.⁶⁸ Nav1.3 is, however, re-expressed in adult rat DRG neurons following peripheral nerve injury.^68,69 In contrast, the expression of Nav1.8 and Nav1.9, which are high-threshold, TTX-resistant sodium channels, is significantly attenuated in injured nerves.^69–71 As the threshold of Nav1.3 is much lower than that of Nav1.8 and Nav1.9, these observations suggest that the excitability of injured nerves becomes sensitive to small membrane potential changes, resulting in easy initiation of spontaneous action potentials (sensitization).

In addition to nerve injury, OVX also increases the transcription of Nav1.3 and reduces mRNA expression of TTX-resistant Na⁺ channels in DRGs.⁷² Therefore, OVX may lower the threshold for generation of action potentials in C-fibers. Furthermore, repeated injections of CT normalize the threshold⁷³ by restoring OVX-induced changes in transcription.⁷² Thus, the changes in sodium channel transcription may be an additional mechanism of hyperalgesia in OVX rats.

Expression of tumor necrosis factor-alpha,⁷⁴ P₂X₃ receptors,⁷⁵ CT gene-related peptide receptors,¹⁵ and transient receptor potential vanilloid 1¹⁵ in DRGs is elevated in OVX rats. However, no studies have examined whether CT ameliorates OVX-induced hyperalgesia by normalizing expression of those genes.

Analgesic mechanisms of neuropathic pain in model rats

Analgesic effect of CT on pain behaviors in chronic constriction injury (CCI) model rats

The analgesic effects of CT on pain behaviors in CCI-induced hyperalgesia in rats have been analyzed.⁷⁶ Mechanical and thermal hyperalgesia develop over time on the ipsilateral hind paw in CCI model rats. Subcutaneously applied CT after surgery gradually relieves hyperalgesia, and these effects persist for several days after cessation of the drug.⁷⁶ The effects of CT are dose-dependent on both mechanical and thermal hyperalgesia.⁷⁶

Changes in Na⁺ channel transcription in DRGs after CCI surgery

Similar to OVX rats, CCI causes induction of abnormal gene expression of Na⁺ channels in DRG neurons.⁷⁶ Transcription of Nav1.3 but not Nav1.7 in the ipsilateral DRG in the CCI model⁷⁶ is significantly increased. In contrast, CCI causes a significant reduction in mRNA expression of the TTX-resistant Na⁺ channels, Nav1.8 and Nav1.9.⁷⁶ Subcutaneous administration of CT restores the expression of Nav1.3, Nav1.8, and Nav1.9 mRNA without affecting Nav1.7 as measured with quantitative reverse transcriptase-polymerase chain reaction.⁷⁶ The abnormal expression of Nav channels following CCI is consistent with previous reports.^68–71

Analgesic mechanisms of chemotherapy-induced peripheral neuropathy in rats

Oxaliplatin is commonly used to treat advanced metastatic colorectal cancer⁷⁷ and induces both acute and chronic neuropathy. In particular, cold allodynia appears soon after administration. Paclitaxel, which is commonly used to treat ovarian, breast, and non-small cell lung cancer,^78,79 induces sensory neuropathy.^80,81 Indeed, the neurotoxicity due to oxaliplatin or paclitaxel is often the reason for discontinuation of treatment, dose reduction, or hospitalization rather than tumor progression.⁸² Although many studies have investigated methods to relieve neurotoxicity induced by anti-cancer drugs, no successful treatments for neuropathy have been developed to date. Aoki et al.⁸³ reported that CT almost completely reverses the effects of both cold and mechanical allodynia induced by oxaliplatin and paclitaxel.

Transient receptor potential ankyrin-1 (TRPA1) and the melastatin-8 (TRPM8) receptor, which are activated by temperatures less than 17℃ and 25℃, respectively, are expressed in nociceptors and may be involved in pain perception.^84,85 Oxaliplatin and paclitaxel do not induce cold allodynia, and oxaliplatin and cisplatin do not induce mechanical allodynia to as great an extent in TRPA1-deficient mice.^86,87 Cold allodynia induced by oxaliplatin is inhibited by capsazepin, a blocker of TRPM8,⁸⁸ and oxaliplatin increases the expression of TRPA1⁸⁶ and TRPM8^88,89 mRNA in DRG neurons. These findings suggest that thermo-sensitive TRPA1 and TRPM8 are involved in the mechanism of neuropathy induced by anti-cancer drugs. CT prevents the cold and mechanical allodynia induced by intra-plantar allyl isothiocyanate and menthol, which are TRPA1 and TRPM8 agonists, respectively.⁸³ Thus, inhibition of cellular signaling related to TRPA1 and TRPM8 may be involved in the analgesic action of CT.⁸³ However, no convincing data support this possibility.

Site of action of CT in CCI rats

CT receptors are expressed in peripheral nervous tissues, including Schwann cells, blood vessels, connective tissues, and others, but not in DRG neurons.⁷⁶ Although, CT receptors are expressed at higher levels in the spinal cord and hypothalamus than in peripheral nervous tissues, the analgesic effects and normalization of Na⁺ channel mRNA by CT occur in parallel to the increase in CT receptor mRNA expression in peripheral nervous tissues but not in the spinal cord and hypothalamus.⁷⁶ On the contrary, down-regulation of CT receptor expression is well known. CT causes not only inhibition of bone resorption via activation of protein kinase A,¹² but also a decrease in ¹²⁵I-CT binding, which is related to the amount of CT receptor mRNA.⁹⁰ Therefore, down-regulation of CT receptor mRNA may be mediated by a signal following the activation of CT receptors.

Injection of CT induces down-regulation of CT receptor mRNA expression in peripheral nervous tissues. This result suggests the existence of a peripheral CT receptor-mediated system that serves as a feedback mechanism to regulate the levels of the CT signal.⁷⁶ On the other hand, CT injections do not influence CT receptor mRNA expression in the spinal cord and hypothalamus⁷⁶ because CT cannot pass through the blood–brain barrier. Accordingly, these studies suggest that CT-induced normalization of the expression of Na⁺ channel mRNA in DRG neurons may be mediated by a “CT signal” released as a result of the activation of CT receptors in injured peripheral nervous tissues but not DRG neurons. This may contribute to the analgesic effect of CT on neuropathic pain.

CT signals may also be induced under normal conditions by CT because CT suppresses CT receptor mRNA in intact nervous tissue.⁷⁶ However, this signal is thought to be non-functional because CT has no influence on the expression of Na⁺ channels⁷⁶ or on behavioral responses^76,83 because no target is present (Figure 3(a)). On the other hand, in injured nervous tissue, CT signals may inhibit an unknown, injury-activated factor that induces abnormal expression of Na⁺ channels (Figure 3(b)). Therefore, application of CT activates the CT signal, which prevents activation of the unknown factor, resulting in normalization of Na⁺ channel expression (Figure 3(b)).

Figure 3.

Possible mechanisms of inhibition of abnormal expression of sodium channels by CT. (a) The action of CT under normal conditions. The CT-induced signal via CT receptors is silent under normal conditions because no target is present. (b) Nerve injury activates an unknown factor that induces the abnormal expression of Na⁺ channels. CT may exert anti-hyperalgesic effects following normalization of Na⁺ channel expression via inactivation of the unknown factor.

CT signal

The cellular localization of CT receptors in peripheral nervous tissues and the CT signal has not been identified. After nerve injury, demyelination and proliferation of Schwann cells are induced.^91,92 Thus, CT receptors are likely expressed in Schwann cells, and a decrease or increase in expression of CT receptors may contribute to demyelination or proliferation of Schwann cells. Glial cell line-derived neurotrophic factor or nerve growth factor regulates the expression of Na⁺ channels or the Na⁺ current density in DRG neurons.^93,94 Schwann cells produce these neurotrophic factors.^95,96 The CT-induced signal that occurs via activation of CT receptors in peripheral nervous tissue may be glial cell line-derived neurotrophic factor or nerve growth factor released from Schwann cells.

Site of action of CT in other models

The site of action in OVX- and chemotherapy-induced peripheral neuropathy has not been reported. Considering the site of action in CCI model rats, CT produces anti-hyperalgesic and anti-allodynic effects via CT receptors in peripheral nervous tissue in rats (Figures 4 and 5). Meanwhile, CT has both acute and chronic anti-allodynic effects in oxaliplatin- and paclitaxel-injected rats.⁸³ This is in contrast to studies in OVX and CCI rats, which showed that repeated systemic administration of CT is needed to produce analgesia.^{3,4,18,76,97–99} Therefore, other unknown factors may be involved in the underlying mechanism of CT in relieving oxaliplatin- and paclitaxel-induced neuropathy (Figure 5).

Figure 4.

Proposed mechanism of inhibition of abnormal expression of 5-HT_1A-like receptors and sodium channels by CT in OVX rats. Estrogen depletion may induce abnormal gene expression of Na⁺ channels and the depletion of 5-HT_1A-like receptors in DRG neurons via unknown factor(s) in nervous tissues. CT may exert anti-hyperalgesic effects by recovery of the abnormal gene expression via the CT-induced signal.

Figure 5.

Proposed mechanism of inhibition of TRPA1 and TRPM8 by CT in chemotherapy-induced peripheral neuropathy in rats. CT may exert anti-allodynic effects by inhibiting the activation of TRPA1 and TRPM8 channels via the CT-induced signal.

Prolonged CT-induced signal and anti-hyperalgesic effect

Although CT disappears within 2 h of injection from human¹⁰⁰ and rat plasma (in house data), subsequent injection of CT gradually enhances the anti-hyperalgesic effect.⁷⁶ In addition, the anti-hyperalgesic and anti-allodynic effects are maintained for several days after cessation of CT administration.^76,83 Therefore, the CT signal may be sustained for several days, and the accumulation of signals probably increases the strength of the anti-hyperalgesic effect.

Central action of CT

Although this review focuses preferentially on the peripheral action of CT, there is some evidence suggesting of central action of CT. Systemic injections of CT reduces neural serotonin transporter but increase 5-HT_1A receptors expression in the thalamus in OVX rats.¹⁴ In formalin-induced hyperalgesia in rats, the ascending serotonergic system, rather than the noradrenergic or opioidergic, mediate the anti-hyperalgesia of CT.³⁴ CT injected systemically binds to the CT receptors at blood–brain barrier free regions, median eminence, area postrema, and lamina terminals.¹⁰¹ Therefore, it cannot be excluded a possibility that CT exert its analgesic actions through interacting with the central nerve system.

Conclusions

Mechanisms of the analgesic effect of CT have been gradually elucidated by recent studies using several types of pain model animals and diverse methods. The anti-hyperalgesic action of CT appears to be mediated by restoration of 5-HT receptors that control excitatory transmitter release from C-afferent terminals, and by normalization of expression of voltage-dependent sodium channels in damaged DRG neurons in OVX or CCI rats. Chemotherapy-induced peripheral neuropathy models have also revealed that inhibition of signals related to TRPA1 and TRPM8 participate in the anti-allodynic actions of CT. Further, a CT-dependent system appears to be present in peripheral nervous tissues and may be activated by nerve injury, resulting in regulation of excitability of primary afferents controlled by sodium channel transcription in DRG neurons. The CT-dependent systems may be silent in normal conditions, and OVX or nerve injury triggers their activation. In addition, CT reduces serotonin transporter but increases 5-HT receptors expression in the thalamus in OVX rats. However, these central actions of CT have not been rigorously addressed. These data suggest that CT may alleviate lower back pain in osteoporotic or neuropathic pain patients via normalization of neuronal hyperexcitability induced by depletion of estrogen or nerve injury. Although CT is an old medicine, its mechanisms of analgesia are only now being elucidated. Investigation of the CT-induced signal and further analysis of the CT receptor-mediated system in peripheral nervous tissue may lead to plausible strategies for alleviating peripheral neuropathic pain.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants-in-aid for scientific research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology, and a grant from the Kumamoto Health Science University to MY.

References

Copp

Cheney

. Calcitonin-a hormone from the parathyroid which lowers the calcium-level of the blood. Nature 1962; 193: 381–382.

Pun

Chan

. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Therap 1989; 11: 205–209.

Gennari

Agnusdei

Gonnelli

Calcitonin and bone pain. In: DeLuca

Mazess

(eds). Osteoporosis: physiological basis, assessment and treatment, NewYork: Elsevier, 1990, pp. 269–274.

Pontiroli

Pajetta

Calderara

. Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget’s disease of bones: a pilot study. J Endocrinol Invest 1991; 14: 47–51.

Tran de

Duong

Finlayson

. Lumbar spinal stenosis: a brief review of the nonsurgical management. Can J Anaesth 2010; 57: 694–703.

Quatraro

Minei

De Rosa

. Calcitonin in painful diabetic neuropathy. Lancet 1992; 339: 746–747.

Perez

Kwakkel

Zuurmond

. Treatment of reflex sympathetic dystrophy (CRPS type 1): a research synthesis of 21 randomized clinical trials. J Pain Symptom Manage 2001; 21: 511–526.

Visser

Kwei

. Salmon calcitonin in the treatment of post herpetic neuralgia. Anaesth Intensive Care 2006; 34: 668–671.

Matayoshi

Shimodozono

Hirata

. Use of calcitonin to prevent complex regional pain syndrome type I in severe hemiplegic patients after stroke. Disabil Rehabil 2009; 31: 1773–1779.

10.

Nakamura

Han

Nishishita

. Calcitonin targets extracellular signal-regulated kinase signaling pathway in human cancers. J Mol Endocrinol 2007; 39: 375–384.

11.

Xie

. Calcitonin treatment is associated with less severe osteoarthritis and reduced toll-like receptor levels in a rat model. J Orthop Sci 2014; 19: 1019–1027.

12.

Suzuki

Nakamura

Takahashi

. Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology 1996; 137: 4685–4690.

13.

Wada

Udagawa

Nagata

. Physiological levels of calcitonin regulate the mouse osteoclast calcitonin receptor by a protein kinase alpha-mediated mechanism. Endocrinology 1996; 137: 312–320.

14.

Yeh

Weng

Chang

. Calcitonin alleviates hyperalgesia in osteoporotic rats by modulating serotonin transporter activity. Osteoporos Int 2016; 27: 3355–3364.

15.

Orita

Ohtori

Koshi

. The effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensory innervation. Spine 2010; 35: 1974–1982.

16.

Albright

. Osteoporosis. Ann Intern Med 1947; 27: 861–882.

17.

Beato

. Gene regulation by steroid hormones. Cell 1989; 56: 335–344.

18.

Shibata

Takeda

Ito

. Ovariectomy-induced hyperalgesia and antinociceptive effect of elcatonin, a synthetic eel calcitonin. Pharmacol, Biochem Behav 1998; 60: 371–376.

19.

Ito

Kumamoto

Takeda

. Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. J Neurosci 2000; 20: 6302–6308.

20.

Ito

Takeda

Furue

. Administration of estrogen shortly after ovariectomy mimics the anti-nociceptive action and change in 5-HT1A-like receptor expression induced by calcitonin in ovariectomized rats. Bone 2004; 35: 697–703.

21.

Takayama

Kikuchi

Konno

. An immunohistochemical study of the antinociceptive effect of calcitonin in ovariectomized rats. BMC Musculoskelet Disord 2008; 9: 164.

22.

Franceschini

Bottaro

Panopoulos

. Long-term treatment with salmon calcitonin in postmenopausal osteoporosis. Curr Ther Res 1983; 34: 795–800.

23.

Menetrey

Gannon

Levine

. Expression of c-fos protein in interneurons and projection neurons of the rat spinal cord in response to noxious somatic, articular, and visceral stimulation. J Comp Neurol 1989; 285: 177–195.

24.

Buritova

Honore

Besson

. Ketoprofen produces profound inhibition of spinal c-Fos protein expression resulting from an inflammatory stimulus but not from noxious heat. Pain 1996; 67: 379–389.

25.

Carrive

Meyer-Carrive

. Changes in formalin-evoked spinal Fos expression and nociceptive behaviour after oral administration of Bufferin A (aspirin) and L-5409709 (ibuprofen + caffeine + paracetamol). Pain 1997; 70: 253–266.

26.

Lima

Avelino

Coimbra

. Differential activation of c-fos in spinal neurones by distinct classes of noxious stimuli. Neuroreport 1993; 4: 747–750.

27.

Presley

Menetrey

Levine

. Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord. J Neurosci 1990; 10: 323–335.

28.

Hamba

Muro

Hiraide

. Expression of c-fos-like protein in the rat brain after injection of interleukin-1-beta into the gingiva. Brain Res Bull 1994; 34: 61–68.

29.

Kuraishi

Harada

Takagi

. Noradrenaline regulation of pain-transmission in the spinal cord mediated by alpha-adrenoceptors. Brain Res 1979; 174: 333–336.

30.

Messing

Lytle

. Serotonin-containing neurons: their possible role in pain and analgesia. Pain 1977; 4: 1–21.

31.

Roberts

. 5-Hydroxytryptamine and antinociception. Neuropharmacology 1984; 23: 1529–1536.

32.

Wang

. Antinociceptive effect of intrathecally administered serotonin. Anesthesiology 1977; 47: 269–271.

33.

Yunger

Harvey

. Behavioral effects of L-5-hydroxytryptophan after destruction of ascending serotonergic pathways in the rat: the role of catecholaminergic neurons. J Pharmacol Exp Ther 1976; 196: 307–315.

34.

Yamazaki

Umeno

Kuraishi

. Involvement of brain serotonergic terminals in the antinociceptive action of peripherally applied calcitonin. Jpn J Pharmacol 1999; 81: 367–374.

35.

Colado

Ormazabal

Goicoechea

. Involvement of central serotonergic pathways in analgesia elicited by salmon calcitonin in the mouse. Eur J Pharmacol 1994; 252: 291–297.

36.

Yoshimura

. Analgesic mechanism of calcitonin. J Bone Miner Metab 2000; 18: 230–233.

37.

Kumazawa

Perl

. Excitation of marginal and substantia gelatinosa neurons in the primate spinal cord: indications of their place in dorsal horn functional organization. J Comp Neurol 1978; 177: 417–434.

38.

Light

Trevino

Perl

. Morphological features of functionally defined neurons in the marginal zone and substantia gelatinosa of the spinal dorsal horn. J Comp Neurol 1979; 186: 151–171.

39.

Cervero

Iggo

. The substantia gelatinosa of the spinal cord: a critical review. Brain: J Neurol 1980; 103: 717–772.

40.

Fitzgerald

. A study of the cutaneous afferent input to substantia gelatinosa. Neuroscience 1981; 6: 2229–2237.

41.

Brown

. The dorsal horn of the spinal cord. Q J Exp Physiol 1982; 67: 193–212.

42.

Light

Perl

. Reexamination of the dorsal root projection to the spinal dorsal horn including observations on the differential termination of coarse and fine fibers. J Comp Neurol 1979; 186: 117–131.

43.

Sugiura

Lee

Perl

. Central projections of identified, unmyelinated (C) afferent fibers innervating mammalian skin. Science 1986; 234: 358–361.

44.

Sugiura

Terui

Hosoya

. Difference in distribution of central terminals between visceral and somatic unmyelinated (C) primary afferent fibers. J Neurophysiol 1989; 62: 834–840.

45.

Yoshimura

Jessell

. Primary afferent-evoked synaptic responses and slow potential generation in rat substantia gelatinosa neurons in vitro. J Neurophysiol 1989; 62: 96–108.

46.

Yoshimura

Jessell

. Amino acid-mediated EPSPs at primary afferent synapses with substantia gelatinosa neurones in the rat spinal cord. J Physiol 1990; 430: 315–335.

47.

Sonohata

Furue

Katafuchi

. Actions of noradrenaline on substantia gelatinosa neurones in the rat spinal cord revealed by in vivo patch recording. J Physiol 2004; 555: 515–526.

48.

Kawamata

Furue

Kozuka

. Changes in properties of substantia gelatinosa neurons after surgical incision in the rat: in vivo patch-clamp analysis. Anesthesiology 2006; 104: 432–440.

49.

Yoshimura

Furue

. Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in the spinal cord. J Pharmacol Sci 2006; 101: 107–117.

50.

Daval

Verge

Basbaum

. Autoradiographic evidence of serotonin1 binding sites on primary afferent fibres in the dorsal horn of the rat spinal cord. Neurosci Lett 1987; 83: 71–76.

51.

Pierce

Xie

Levine

. 5-Hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: a polymerase chain reaction study. Neuroscience 1996; 70: 553–559.

52.

Chen

Vasko

. Multiple subtypes of serotonin receptors are expressed in rat sensory neurons in culture. J Pharmacol Exp Therap 1998; 287: 1119–1127.

53.

Symmons

van Hemert

Vandenbroucke

. A longitudinal study of back pain and radiological changes in the lumbar spines of middle aged women. I. Clinical findings. Ann Rheum Dis 1991; 50: 158–161.

54.

Gamble

. Osteoporosis: drug and nondrug therapies for the patient at risk. Geriatrics 1995; 50: 39–43.

55.

Willhite

. Osteoporosis in women: prevention and treatment. J Am Pharm Assoc 1998; 38: 614–623.

56.

South-Paul

. Osteoporosis: part II. Nonpharmacologic and pharmacologic treatment. Am Fam Phys 2001; 63: 1121–1128.

57.

Forman

Tingle

Estilow

. The response to analgesia testing is affected by gonadal steroids in the rat. Life Sci 1989; 45: 447–454.

58.

Siriphorn

Chompoopong

Floyd

. 17beta-estradiol protects Schwann cells against H2O2-induced cytotoxicity and increases transplanted Schwann cell survival in a cervical hemicontusion spinal cord injury model. J Neurochem 2010; 115: 864–872.

59.

Taleghany

Sarajari

DonCarlos

. Differential expression of estrogen receptor alpha and beta in rat dorsal root ganglion neurons. J Neurosci Res 1999; 57: 603–615.

60.

Nishikawa

Ikegami

Sakata

. Ovariectomy increases the level of estrogen receptor mRNA and estrogen receptor binding sites in female rat adipose tissue. J Endocrinol Invest 1993; 16: 579–583.

61.

Sohrabji

Miranda

Toran-Allerand

. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 1994; 14: 459–471.

62.

Chen

Kalu

. Modulation of intestinal estrogen receptor by ovariectomy, estrogen and growth hormone. J Pharmacol Exp Ther 1998; 286: 328–333.

63.

Lim

Won

Lee

. A PCR analysis of ERalpha and ERbeta mRNA abundance in rats and the effect of ovariectomy. J Bone Miner Res 1999; 14: 1189–1196.

64.

Mohamed

Abdel-Rahman

. Effect of long-term ovariectomy and estrogen replacement on the expression of estrogen receptor gene in female rats. Eur J Endocrinol 2000; 142: 307–314.

65.

Pelletier

El-Alfy

Labrie

. Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor alpha and prolactin mRNA expression in intact, ovariectomized and gonadotropin-releasing hormone-treated female rats. Neuroendocrinology 2001; 74: 367–374.

66.

Rose’Meyer

Mellick

Garnham

. The measurement of adenosine and estrogen receptor expression in rat brains following ovariectomy using quantitative PCR analysis. Brain Res Brain Res Protoc 2003; 11: 9–18.

67.

Dib-Hajj

Black

Waxman

. Voltage-gated sodium channels: therapeutic targets for pain. Pain Med 2009; 10: 1260–1269.

68.

Waxman

Kocsis

Black

. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol 1994; 72: 466–470.

69.

Dib-Hajj

Black

Felts

. Down-regulation of transcripts for Na channel alpha-SNS in spinal sensory neurons following axotomy. Proc Natl Acad Sci U S A 1996; 93: 14950–14954.

70.

Decosterd

Abdi

. The pattern of expression of the voltage-gated sodium channels Na(v)1.8 and Na(v)1.9 does not change in uninjured primary sensory neurons in experimental neuropathic pain models. Pain 2002; 96: 269–277.

71.

Sleeper

Cummins

Dib-Hajj

. Changes in expression of two tetrodotoxin-resistant sodium channels and their currents in dorsal root ganglion neurons after sciatic nerve injury but not rhizotomy. J Neurosci 2000; 20: 7279–7289.

72.

Ito

Takeda

Hori

. Antinociceptive mechanism of calcitonin in OVX rats–change in expression of Na channels (in Japanese). Osteoporosis Jpn 2005; 13: 78–80.

73.

Ito A, Takeda M, Furue H, et al. Effect of calcitonin on the threshold stimulus intensity to activate primary afferent fiber in ovariectomized rats. In: International symposium on plasticity of pain system, Fukuoka, Japan, 9–10 May 2002, IP-10.

74.

Chen

Xie

. Blocking TNF-alpha with infliximab alleviates ovariectomy induced mechanical and thermal hyperalgesia in rats. Neurol Sci 2012; 33: 527–533.

75.

Fan

. Estrogen modulation of peripheral pain signal transduction: involvement of P2X(3) receptors. Purinergic Signal 2011; 7: 73–83.

76.

Ito

Takeda

Yoshimura

. Anti-hyperalgesic effects of calcitonin on neuropathic pain interacting with its peripheral receptors. Mol Pain 2012; 8: 42.

77.

Andre

Boni

Mounedji-Boudiaf

. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–2351.

78.

Rowinsky

. Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother 1994; 28: S18–S22.

79.

Socinski

. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 1999; 4: 408–416.

80.

Dougherty

Cata

Cordella

. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004; 109: 132–142.

81.

Kuroi

Shimozuma

. Neurotoxicity of taxanes: symptoms and quality of life assessment. Breast Cancer 2004; 11: 92–99.

82.

Pasetto

D’Andrea

Rossi

. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 2006; 59: 159–168.

83.

Aoki

Mori

Nakahara

. Effect of synthetic eel calcitonin, elcatonin, on cold and mechanical allodynia induced by oxaliplatin and paclitaxel in rats. Eur J Pharmacol 2012; 696: 62–69.

84.

McKemy

Neuhausser

Julius

. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002; 416: 52–58.

85.

Peier

Moqrich

Hergarden

. A TRP channel that senses cold stimuli and menthol. Cell 2002; 108: 705–715.

86.

Nassini

Gees

Harrison

. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 2011; 152: 1621–1631.

87.

Materazzi

Fusi

Benemei

. TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. Pflugers Arch: Eur J Physiol 2012; 463: 561–569.

88.

Gauchan

Andoh

Kato

. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett 2009; 458: 93–95.

89.

Kawashiri

Egashira

Kurobe

. L type Ca(2)+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol Pain 2012; 8: 7.

90.

Wada

Martin

Findlay

. Homologous regulation of the calcitonin receptor in mouse osteoclast-like cells and human breast cancer T47D cells. Endocrinology 1995; 136: 2611–2621.

91.

Carroll

Miller

Frohnert

. Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J Neurosci 1997; 17: 1642–1659.

92.

Costa

Trovato

Colleoni

. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 2005; 116: 52–61.

93.

Boucher

Okuse

Bennett

. Potent analgesic effects of GDNF in neuropathic pain states. Science 2000; 290: 124–127.

94.

Leffler

Cummins

Dib-Hajj

. GDNF and NGF reverse changes in repriming of TTX-sensitive Na(+) currents following axotomy of dorsal root ganglion neurons. J Neurophysiol 2002; 88: 650–658.

95.

Henderson

Phillips

Pollock

. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994; 266: 1062–1064.

96.

Matsuoka

Meyer

Thoenen

. Cell-type-specific regulation of nerve growth factor (NGF) synthesis in non-neuronal cells: comparison of Schwann cells with other cell types. J Neurosci 1991; 11: 3165–3177.

97.

Kessel

Worz

. Immediate response of phantom limb pain to calcitonin. Pain 1987; 30: 79–87.

98.

Jaeger

Maier

. Calcitonin in phantom limb pain: a double-blind study. Pain 1992; 48: 21–27.

99.

Fujita

. Therapy of osteoporosis in Japan, Copenhagen: Osteo-press, 1990, pp. 2107–2122.

100.

Takeyama

Ikawa

Nagano

. Elcatonin raises levels of vasoactive intestinal peptide in human plasma. J Pharm Pharmacol 1996; 48: 657–659.

101.

van Houten

Rizzo

Goltzman

. Brain receptors for blood-borne calcitonin in rats: circumventricular localization and vasopressin-resistant deficiency in hereditary diabetes insipidus. Endocrinology 1982; 111: 1704–1710.

Mechanisms of the analgesic effect of calcitonin on chronic pain by alteration of receptor or channel expression

Abstract

Keywords

Introduction

Mechanisms of the analgesic effect of CT on ovariectomized (OVX) rats

Background for the analysis of OVX rats

The analgesic effect of CT on OVX rats

Involvement of the serotonergic system in the CT-induced analgesic effect in OVX rats

Serotonergic dysfunction in the spinal dorsal horn of OVX rats and its recovery following CT treatment

Ineffectiveness of estrogen treatment on hyperlagesia long term after OVX

Other mechanisms of the anti-hyperalgesic effects of CT in OVX rats

Analgesic mechanisms of neuropathic pain in model rats

Analgesic effect of CT on pain behaviors in chronic constriction injury (CCI) model rats

Changes in Na+ channel transcription in DRGs after CCI surgery

Analgesic mechanisms of chemotherapy-induced peripheral neuropathy in rats

Site of action of CT in CCI rats

CT signal

Site of action of CT in other models

Prolonged CT-induced signal and anti-hyperalgesic effect

Central action of CT

Conclusions

Footnotes

Declaration of Conflicting Interests

Funding

References

Changes in Na⁺ channel transcription in DRGs after CCI surgery